This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition (..)
The complaint alleged that RWJBarnabas conspired with real estate investors, New Jersey’s largest payer and government officials to eliminate competition and monopolize acute care services in the state.
While current government and commercial efforts to negotiate competitive drug prices are important, this focus represents a minor—and misplaced—implementation of medication management. It’s time that policymakers, insurers and healthcare providers make pharmacogenomic testing a fundamental standard of care delivery.
New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.
to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.
The UK Government has announced funds worth $24.17m (£20m) to conduct research for developing new obesity therapies and technologies. The latest investment by the government is anticipated to aid the NHS in saving billions over time and guarantee that crucial funds are allocated to important key frontline services.
According to The Hill “, a large majority of the public favors allowing the government to negotiate for lower prescription drug prices, according to a new poll that comes as a legislative battle plays out on the issue. Innovation and Competition Act. Government assistance programs include: U.S. Administration on Aging.
Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.
If you’re thinking about a career in medical sales for a local generic pharmaceutical company in Malaysia, you might already know it’s a fast-paced and competitive field. Doctors, pharmacists, and procurement officers often scrutinize every ringgit, especially when government budgets are tight or private hospitals weigh profit margins.
Overlapping regulations and data governance challenges A particularly complex intersection arises between the GDPR and the EU AI Act, especially concerning data governance. This overlap also extends to the need for organisations to create governance structures that satisfy both privacy and transparency.
A major new £400 million public-private collaboration has launched in the UK, aimed at enhancing the life sciences sector’s economic growth and the competitiveness over the next five years. The post Innovative pharma-government partnership to enhance UK clinical trials appeared first on European Pharmaceutical Review.
17th October 2024 2 Minutes Curzon Consulting is thrilled to sponsor this year’s Alliance Manchester Business School Consultancy Case Competition. Introduced in 2016, the competition enables AMBS MBA students to showcase their skills, innovative thinking, and problem-solving abilities. We can’t wait to see how everyone gets on!
Drug pricing is done by internal teams who look at what the market will bear and the competitive landscape. If drug prices are to come down, the federal government needs to negotiate drug prices for Medicare, and a new breed of CEO, who really puts patients first, needs to take control. Again this is not true.
Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. Via Axios “The 10 highest-selling drugs in the U.S. sales revenue more than triple the rest of the world.
The process of making sales to government-run hospitals is quite different from that of making sales to private hospitals. Since government-run hospitals work for the greater good of the entire community, a few crucial factors need to be considered. In government-run hospitals, decision-making often depends on the executives.
The UK government has announced that the Apprenticeship Levy will be replaced by a new Growth and Skills Levy, a move designed to give employers greater control over workforce training.
8:00 AM: First Stop Government Hospital By 8:00 AM, youre meeting a pharmacy buyer or a medical officer at a government hospital. Challenge: Navigating the bureaucracy of government hospitals can be tricky. Emphasizing your products efficacy and global backing can give you a competitive edge.
Bill Clinton: My fellow Americans, I stand here today to argue in favor of universal government-funded healthcare. Furthermore, universal government-funded healthcare would help to level the playing field for all Americans, regardless of their socioeconomic status. Ronald Reagan: My fellow Americans, I must disagree with my colleague.
Within the highly regulated and technologically advanced pharmaceutical sector, effective data governance transcends recommended best practices and represents a strategic imperative. The Evolving Data Governance Imperative For organizations like Closeup, robust data governance is fundamental to realizing AI’s full potential.
Marketing pharma has become a complex and competitive field, with companies vying for the attention of healthcare providers (HCPs), patients, and regulators alike. With the right strategies, you can rise above the competition and drive measurable success. The good news? For tips on navigating regulations, visit Pharma Marketing.
The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July 2022. Indicators from the 2000s were captured in the Pharmaceutical Industry Competitiveness Task Force (PICTF) Indicators. The post UK life science competitiveness indicators 2022: measuring what matters most?
We’re pleased to showcase some institutions that excel in a competitive global environment, supporting their Highly Cited Researchers in a way that encourages collaboration, facilitates career growth and accelerates highly innovative research. The National University of Singapore (NUS) is home to 32 Highly Cited Researchers in 2021.
With advancements in technology, increasing competition, and changing patient expectations, pharma marketers need to stay ahead of the curve. Adhering to guidelines from the FDA and other governing bodies ensures that campaigns remain effective without crossing ethical boundaries. Learn more about compliance tips at Pharma Marketing.
Here is the executive summary of the Government’s report on AbbVie. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. SUMMARY: Sometimes there are just no words to express my outrage. I’m disgusted, sad , and angry.
has a diverse and extensive research landscape, with government agencies, universities, and private companies playing a significant role in funding and conducting research. The research landscape is highly competitive on the global stage, with a focus on driving innovation and making breakthroughs. For many years the U.S.
A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation.
SKIMMERS SUMMARY: There is one and only one social responsibility of business–to use its resources and engage in activities designed to increase its profits so long as it stays within the rules of the game, which is to say, engages in open and free competition without deception or fraud. Milton Friedman.
The new Eco Line product family demonstrates our commitment to delivering sustainable, eco-friendly barrier bottles at competitive prices,” added Bassi. As such, bottle weight is reduced by up to 30 percent without compromising on Water Vapor Transmission Rate (WVTR).
A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening “footprint, R&D and manufacturing investments” in the country. billion (around $4 billion) in revenue to the government – 26.5% Returns have risen sharply from £0.6 billion in 2021 to £1.8
million government grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency that will be used to fuel the company’s vaccine platform, per a 30 May announcement. VLAIO is a Flemish government agency that seeks to promote entrepreneurship and research through funding and advice. AstriVax has received a €2.5
When prospects are comparing your proposal to the competition in an attempt to create a bidding war, the buyer is working to further put themselves in the driver's seat and get the lowest price they can. How to Differentiate When Prospects are Comparing Your Proposal to the Competition. The Problem With Comparing Quotes.
Benefits of a Data-Driven Approach With increasing competition and regulatory scrutiny, pharma brands need strategies that are not only effective but also measurable and agile. It’s your competitive edge. Data-driven marketing delivers on all three fronts. This precision translates to better ROI and lower cost-per-engagement.
When you hear that government servants in Malaysia will now be prescribed generic medications at Institut Jantung Negara (IJN), what’s your first thought? IJN, being a center for specialized heart care, treats thousands of government employees and retirees every year, and the bill can be hefty. Is There Really a Big Difference?
A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.
[contact-form-7] Latest news Curzon Sponsors the 2024 AMBS Case Interview Competition Highly Commended in the 2024 MCA Awards RECHARGE UK calls for new government to put renewed focus on skills See latest news
AstraZeneca has scrapped its planned 450 million expansion of a vaccine manufacturing facility in Liverpool, UK, citing economic factors and reduced government funding. Government support and financial challenges Initially, the UK government pledged 90 million to help fund the project.
The report recommened that to gain a competitive edge in the market, focusing on modernising R&D models or implementing emerging technologies could support this endeavour. The pharmaceutical industry will need to innovate and increase resilience to accelerate market expansion, the company highlighted.
The latest market study report from the Competition Bureau has provided recommendations to health care providers (HCPs) on how to improve the ways they work within Canada’s public health system. The new report states that digital health care is not being used to its full potential in Canada.
Since 2014, the repayment percentage detailed in the VPAS and predecessor the PPRS averaged at around 7%, but skyrocketed to 19% in 2022 ahead of a government-agreed cap at 15%, and rose again to 26.5% The ABPI said that exposes “the depth of feeling that the current voluntary scheme is damaging the UK life sciences industry.”
Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.
Funders, governments and institutions across the globe are increasingly expected to demonstrate the societal impact of research. Exploration of competitive strengths and relative weaknesses compared to peer institutions helps to prioritize what to promote and also to identify more successful practices for possible implementation.
This can be especially important in the current global economic climate, where competition for market share is fierce, and access to new customers is critical for growth. This includes ensuring access and affordability of their products, which can positively impact their environmental social governance (ESG) score and reputation.
The four governments of the UK established the scheme to increase the climate ambition of the UK’s carbon pricing policy, whilst also protecting the competitiveness of UK businesses. On 1 January 2021, a UK Emissions Trading Scheme (UK ETS) replaced the UK’s participation in the European Union (EU) ETS.
Bringing an end to a 13-year deliberation on a whistleblower lawsuit, Biogen recently agreed to pay a $900 million settlement , amidst increased government alertness on pharmaceutical fraud. However, new MS drugs like Novartis ’ Gilenya, were going to soon enter the market and increase competition within the MS therapeutic landscape.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content